Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.2/5
OSE Immuno (OSE FP)
Watchlist
47
Analysis
Health Care
•
France
OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
OSE Immuno
•
05 Jun 2025 10:00
•
Issuer-paid
OSE Immunotherapeutics — New UC biomarker underpins growth strategy
OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and...
Edison Investment Research
Follow
235 Views
Share
bullish
•
OSE Immuno
•
03 Jun 2025 10:00
•
Issuer-paid
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
Edison Investment Research
Follow
244 Views
Share
bullish
•
OSE Immuno
•
03 Jun 2025 09:00
•
Issuer-paid
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
Edison Investment Research
Follow
225 Views
Share
bullish
•
OSE Immuno
•
22 May 2025 14:00
•
Issuer-paid
OSE Immunotherapeutics — Strategic collaboration in mRNA technologies
OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop...
Edison Investment Research
Follow
248 Views
Share
bullish
•
OSE Immuno
•
06 May 2025 16:00
•
Issuer-paid
OSE Immunotherapeutics — Lusvertikimab impresses in extension period data
OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of...
Edison Investment Research
Follow
230 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x